EUVIMEDEUVIMED entdecken
Open Access

Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus

Jennifer J Yland iD, Krista F Huybrechts, Amelia K Wesselink, Loreen Straub, Yu-Han Chiu, Ellen W Seely, Elisabetta Patorno iD, Brian T Bateman, Helen Mogun, Lauren A Wise, Sonia Hernández-Díaz

Diabetes Care · 2024

DOI: 10.2337/dc23-2056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, 2024. Verfasst von Jennifer J Yland und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Boston University School of Public Health, Boston, MA. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Pregnancy Outcome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE We emulated a modified randomized trial (Metformin in Women With Type 2 Diabetes in Pregnancy [MiTy]) to compare the perinatal outcomes in women continuing versus discontinuing metformin during pregnancy among those with type 2 diabetes treated with metformin plus insulin before pregnancy. RESEARCH DESIGN AND METHODS This study used two health care claims databases (U.S., 2000–2020). Pregnant women age 18–45 years with type 2 diabetes who were treated with metformin plus insulin at conception were eligible. The primary outcome was a composite of preterm birth, birth injury, neonatal respiratory distress, neonatal hypoglycemia, and neonatal intensive care unit admission. Secondary outcomes included the components of the primary composite outcome, gestational hypertension, preeclampsia, maternal hypoglycemia, cesarean delivery, infants large for gestational age, infants small for gestational age (SGA), sepsis, and hyperbilirubinemia. We adjusted for potential baseline confounders, including demographic characteristics, comorbidities, and proxies for diabetes progression. RESULTS Of 2,983 eligible patients, 72% discontinued use of metformin during pregnancy. The average age at conception was 32 years, and the prevalence of several comorbidities was higher among continuers. The risk of the composite outcome was 46% for continuers and 48% for discontinuers. The adjusted risk ratio was 0.92 (95% CI 0.81, 1.03). Risks were similar between treatments and consistent between databases for most secondary outcomes, except for SGA, which was elevated in continuers only in the commercially insured population. CONCLUSIONS Our findings were consistent with those reported in the MiTy randomized trial. Continuing metformin during pregnancy was not associated with increased risk of a neonatal composite adverse outcome. However, a possible metformin-associated risk of SGA warrants further consideration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2Hypoglycemic AgentsPregnancy OutcomeHumansFemalePregnancyAdultYoung AdultInfant, NewbornAdolescentMiddle AgedPregnancy in Diabetics

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Epidemiology, Boston University School of Public Health, Boston, MA.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
  • CAUSALab, Harvard T.H. Chan School of Public Health, Boston, MA.
  • Endocrinology, Diabetes and Hypertension Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
  • Stanford University School of Medicine, Stanford, CA.

ORCID-Profile: Jennifer J Yland, Elisabetta Patorno

Förderung

  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • NIA NIH HHS
  • FDA HHS
  • NICHD

Zitieren

APA

Yland, J. J., Huybrechts, K. F., Wesselink, A. K., Straub, L., Chiu, Y. H., Seely, E. W., Patorno, E., Bateman, B. T., Mogun, H., Wise, L. A., & Hernández-Díaz, S. (2024). Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus. Diabetes Care. https://doi.org/10.2337/dc23-2056

Vancouver

Yland JJ, Huybrechts KF, Wesselink AK, Straub L, Chiu YH, Seely EW, et al. Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus. Diabetes Care. 2024. doi:10.2337/dc23-2056

BibTeX
@article{Yland2024,
  author = {Yland, Jennifer J and Huybrechts, Krista F and Wesselink, Amelia K and Straub, Loreen and Chiu, Yu-Han and Seely, Ellen W and Patorno, Elisabetta and Bateman, Brian T and Mogun, Helen and Wise, Lauren A and Hernández-Díaz, Sonia},
  title = {Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus},
  journal = {Diabetes Care},
  year = {2024},
  doi = {10.2337/dc23-2056}
}
Kostenlos starten →